PHOEBE MCCRORIE PHOEBE.MCCRORIE1@NOTTINGHAM.AC.UK
Research Fellow
Detection of Label-Free Drugs within Brain Tissue Using Orbitrap Secondary Ion Mass Spectrometry as a Complement to Neuro-Oncological Drug Delivery
McCrorie, Phoebe; Rowlinson, Jonathan; Scurr, David J.; Marlow, Maria; Rahman, Ruman
Authors
Jonathan Rowlinson
DAVID SCURR DAVID.SCURR@NOTTINGHAM.AC.UK
Principal Research Fellow
MARIA MARLOW Maria.Marlow@nottingham.ac.uk
Associate Professor
RUMAN RAHMAN RUMAN.RAHMAN@NOTTINGHAM.AC.UK
Professor of Molecular Neuro-Oncology
Abstract
Historically, pre-clinical neuro-oncological drug delivery studies have exhaustively relied upon overall animal survival as an exclusive measure of efficacy. However, with no adopted methodology to both image and quantitate brain parenchyma penetration of label-free drugs, an absence of efficacy typically hampers clinical translational potential, rather than encourage re-formulation of drug compounds using nanocarriers to achieve greater tissue penetration. OrbiSIMS, a next-generation analytical instrument for label-free imaging, combines the high resolving power of an OrbiTrap™ mass spectrometer with the relatively high spatial resolution of secondary ion mass spectrometry. Here, we develop an ex vivo pipeline using OrbiSIMS to accurately detect brain penetration of drug compounds. Secondary ion spectra were acquired for a panel of drugs (etoposide, olaparib, gemcitabine, vorinostat and dasatinib) under preclinical consideration for the treatment of isocitrate dehydrogenase-1 wild-type glioblastoma. Each drug demonstrated diagnostic secondary ions (all present molecular ions [M-H]– which could be discriminated from brain analytes when spiked at >20 µg/mg tissue. Olaparib/dasatinib and olaparib/etoposide dual combinations are shown as exemplars for the capability of OrbiSIMS to discriminate distinct drug ions simultaneously. Furthermore, we demonstrate the imaging capability of OrbiSIMS to simultaneously illustrate label-free drug location and brain chemistry. Our work encourages the neuro-oncology community to consider mass spectrometry imaging modalities to complement in vivo efficacy studies, as an analytical tool to assess brain distribution of systemically administered drugs, or localised brain penetration of drugs released from micro-or nano-scale biomaterials.
Citation
McCrorie, P., Rowlinson, J., Scurr, D. J., Marlow, M., & Rahman, R. (2022). Detection of Label-Free Drugs within Brain Tissue Using Orbitrap Secondary Ion Mass Spectrometry as a Complement to Neuro-Oncological Drug Delivery. Pharmaceutics, 14(3), Article 571. https://doi.org/10.3390/pharmaceutics14030571
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 3, 2022 |
Online Publication Date | Mar 5, 2022 |
Publication Date | Mar 1, 2022 |
Deposit Date | Mar 4, 2022 |
Publicly Available Date | Mar 4, 2022 |
Journal | Pharmaceutics |
Electronic ISSN | 1999-4923 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 14 |
Issue | 3 |
Article Number | 571 |
DOI | https://doi.org/10.3390/pharmaceutics14030571 |
Keywords | OrbiSIMS; mass spectrometry imaging; glioblastoma; drug delivery |
Public URL | https://nottingham-repository.worktribe.com/output/7536223 |
Publisher URL | https://www.mdpi.com/1999-4923/14/3/571 |
Files
Detection of Label-Free Drugs within Brain Tissue Using Orbitrap Secondary Ion Mass Spectrometry
(1.8 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Biomedical engineering approaches to enhance therapeutic delivery for malignant glioma
(2020)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search